Actively Recruiting
Evaluation of Safety and Tolerability of QXL138AM in Adults with Advanced Solid Tumors and Multiple Myeloma Using Dose Escalation and Expansion
Led by Nammi Therapeutics Inc · Updated on 2026-10-20
100
Participants Needed
11
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating QXL138AM, a biological treatment given by intravenous infusion every two weeks, in adults with locally advanced, unresectable, or metastatic solid tumors or multiple myeloma. This first-in-human Phase 1a1b study aims to assess the safety, how the drug moves through the body, and early signs of anti-tumor activity. The study is open-label and conducted across multiple centers, sponsored by Nammi Therapeutics Inc. The study is divided into two main parts, each with two sub-parts. Part A involves dose escalation Part A1 enrolls participants with various advanced solid tumors and uses a modified 33 dose escalation design to find the recommended dose, while Part A2 focuses on dose escalation in multiple myeloma, starting once the dose for solid tumors is identified or if activity is seen. Part B involves dose expansion, exploring safety and anti-tumor effects at the recommended doses in larger groups of participants with solid tumors Part B1 and multiple myeloma Part B2. The infusion is administered over 30 to 60 minutes. Participants will undergo screening to confirm eligibility, including measurable disease and adequate organ function. Throughout the study, safety is closely monitored by tracking adverse events and measuring drug levels in the blood. Anti-tumor activity will be assessed during the dose expansion phase. The study includes an estimated duration of about 3.5 years to collect comprehensive safety and pharmacokinetic data. Participants will be followed regularly with assessments to evaluate treatment effects and monitor for any side effects.
CONDITIONS
Brief Title
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Research Team
D
David Stover, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here